Athersys

ATIVESITE | Rebalancing the Immune System: The MultiStem® Cellular Platform for Treating Disease and Injury

Preclinical research using MultiStem cells has shown Multipotent Adult Progenitor Cells, or MAPC®, may be beneficial in the treatment of a variety of critical care and difficult to treat inflammatory…

Read More »

ATIVESITE | Dr. Richard Perry discusses the MASTERS-2 clinical trial

Dr. Richard Perry, Consultant Neurologist at the National Hospital for Neurology and Neurosurgery in London, is one of the principal investigators involved in the Athersys MASTERS-2 clinical trial, evaluating MultiStem…

Read More »

ATIVESITE | German neurologists Dr. Thorsten Döppner and Dr. Beschan Ahmad discuss the MASTERS-2 clinical trial

Dr. Thorsten Döppner, Neurologist and Professor, and Dr. Beschan Ahmad, Sub-PI, at Universitaetsmedizin Goettingen – Georg-August-Universitaet discuss the Athersys MASTERS-2 clinical trial evaluating MultiStem cell therapy for the treatment of…

Read More »

ATIVESITE | Stroke Neurologist KOL Panel: TREASURE data for ischemic stroke

Five key opinion leaders (KOLs) in the field of stroke and a statistician to share their perspectives on the topline data from the TREASURE study conducted by the Athersys’ partner…

Read More »

ATIVESITE | Dr. Ayush Batra discusses the MASTERS-2 clinical trial for the treatment of stroke

Clip courtesy of Fox32 in Chicago. Athersys, Inc. is developing MultiStem® cell therapy and is currently in late-stage clinical trials for ischemic stroke, ARDS, and trauma. The MASTERS-2 study is…

Read More »

ATIVESITE | MultiStem Administration for Trauma Related Inflammation and Complications – The MATRICS-1 Study

Trauma is the leading cause of death in people aged 1 to 44 and the leading cause of life years lost. Athersys is collaborating with The University of Texas Health…

Read More »

ATIVESITE | Why Critical Care?

Dr. Eric Jenkins, Senior Medical Director and Head of Clinical Programs at Athersys explains why the Company has chosen to focus on developing MuliStem® Cell Therapy for critical care indications.…

Read More »

 

ATIVESITE | MultiStem Clinical Programs: An In-Depth Look

Athersys is a clinical late-stage regenerative medicine company developing MultiStem® (invimestrocel) cell therapy. This investor presentation provides an in-depth look at the its current clinical programs in ischemic stroke, acute…

Read More »

ATIVESITE | A potential new treatment for ARDS

Dr. Eric Jenkins, Senior Medical Director and Head of Clinical Programs at Athersys discusses the results of the MUST-ARDS clinical trial, evaluating MultiStem® Cell Therapy for the treatment of ARDS.…

Read More »

ATIVESITE | How MAPC (MultiStem) Modulates Immune Responses

Dr. Alice Valentin-Torres of Athersys discusses the research and findings described in the Scientific Reports by Nature publication supporting the hypothesis of how MAPC® (MultiStem®) modulates immune responses under different…

Read More »